15-Year Myeloma Survivor Reports from ASH

| Michael Tuohy

When I was diagnosed in 2000, only a handful of treatment options were available. We used our options sparingly, hoping to keep something in our back pocket for when we needed it.

Today is a very different story. We have treatment options that use various types of drugs that can work alone and in combination to beat the myeloma down as low as possible for each of us. We have witnessed the expanding multiple myeloma therapeutic armamentarium: from the 1950s with melphalan, to the most recent FDA approvals this year of Farydak (panobinostat), Darzalex (daratumumab), and Ninlaro (ixazomib).

On November 20th, I listened to to Dr. Durie’s teleconference on Myeloma 101 & Pain Management. It also included a “Birds Eye View of ASH,” and after hearing this, I’m looking forward to many new and updated abstracts. In particular, my focus will be on minimal residual disease (MRD), subclones of myeloma, and the Anti-CD38 MoAbs. Molecular tests and subclones as well as driver mutations resistance leading to new clones will be big themes at ASH this year.

Another big focus at ASH will be the three drug combinations as opposed to two drugs with different triplets. This is sure to be very interesting and important!

I’m looking forward to hearing more about MRD-monitoring in myeloma using Next Generation Flow (NGF). This can be beneficial to all our futures, whether we are high-risk smoldering patients, patients who are trying to figure out to push harder with our current treatment, or if we are patients who can afford to lower our doses of medication. In particular, ASH will feature a presentation on the steps to assess and treat MRD.

As you can see, there’s much to prepare for! I hope to report back to my local community my new insights from ASH about what’s happening in myeloma land.

Follow Michael on Twitter: @IMFmikeMYELOMA
Connecticut Multiple Myeloma Fighters Information Group
Waterbury, CT


Leave a Reply